NImmune Biopharma, Inc

A recent study from researchers at Hunter College finds promising new therapeutic potential in the treatment of Alzheimer’s disease for omilancor, our lead product candidate for inflammatory and autoimmune diseases. Omilancor is a once-daily, oral, best- and first-in-class therapy in Phase 3 clinical development for ulcerative colitis (UC) and Phase 2 for Crohn’s disease (CD), with multiple I&I indications in progress. By activating the LANCL2 pathway, a novel immunometabolic mechanism of action, omilancor is designed to create a favorable regulatory microenvironment in the gut, enhancing regulatory T cell function (Treg) and decreasing the production of key inflammatory mediators while reprogramming metabolism. New scientific findings now highlight the therapeutic potential of targeting LANCL2 to improve cognitive behavior and reduce Aβ plaques and neuronal loss, especially in Alzheimer’s patients. Preprint data and a recent dissertation by Emily Birnbaum suggest multiple mechanisms by which LANCL2 activation by omilancor could improve cognition and reduce Alzheimer’s pathology. These findings further validate similar results from The NIMML Institute’s TITAN-X platform, which suggest LANCL2 as a therapeutic target for Alzheimer’s disease. Read the dissertation on the topic here: https://lnkd.in/grYAPW6w  The full preprint paper can be found in bioRxiv & medRxiv here: https://lnkd.in/g-VdYiT2 #Immunology #DrugDevelopment #Biotech #Innovation #Alzheimers

We're thrilled to be featured in the latest issue of Valley Business FRONT, Virginia's Blue Ridge Business Journal! Our CEO, Dr. Josep B., shared insights into NImmune Biopharma, Inc's role in the "scientific innovation ecosystem" we've built in Blacksburg. As part of Virginia’s BioHealth innovation ecosystem, we're proud to be at the forefront of scientific and clinical advances in inflammation and immunology by identifying novel targets and creating the next wave of best-in-class and first-in-class drugs for patients with unmet clinical needs. At NImmune BioPharma, we're committed to improving patients' lives in the US and worldwide through groundbreaking R&D. We're excited about the potential to transform drug development by using advanced A.I. algorithms and computational models of the immune system, such as TITAN-X, to characterize novel mechanisms of action and to develop safer and more effective drugs. Read the full article in November’s issue of Valley Business FRONT to learn more about our journey and the impact we're making in the global biotech industry: https://lnkd.in/gV_Sdnaf For more on the TITAN-X advanced A.I. platform, we encourage you to read our recent release: https://lnkd.in/gP7xsKFw #Immunology #DrugDevelopment #Biotech #Innovation

On October 21, NImmune Biopharma, Inc acquired development and commercialization rights for omilancor in Asia. Upon closing, we will wholly own global rights to omilancor. This transaction is highly shareholder value accretive, enabling the acceleration of patient enrollment in the global registration directed Phase 3 program in ulcerative colitis, the Phase 2 program in Crohn’s disease, and additional I&I indications.   The timing of this transaction could not be more ideal as we initiate the global registration directed Phase 3 program with patient enrollment centers in the U.S., Asia, Europe, Latin America and MENA. Published final and complete Phase 2 data validate the novel LANCL2 mechanism of action (MoA) in IBD and position omilancor as best-in-class therapeutic for UC in a once daily oral and unrivaled safety and tolerability profile.   Read the full announcement here: https://t.ly/i2nct   #PrecisionMedicine #AutoimmuneDisease #ImmunologyResearch

We are thrilled to announce the discovery of a new immunometabolic mechanism of action by which LANCL2 activation provides protection from inflammatory and autoimmune disease detailed in recent research published in the Journal of Immunology. In partnership with The NIMML Institute, we have discovered a new mechanism of LANCL2 activation in phagocytes that combines with established actions of LANCL2 in Tregs and provides immunometabolic control of and therapeutic efficacy in Systemic Lupus Erythematosus (SLE).  The research validates the role of NIM-1324 as the first LANCL2 drug with therapeutic efficacy in systemic inflammation in three mouse models of lupus to support immune tolerance. The activation of LANCL2 by NIM-1324 reduces nuclear antigen reactivity, autoantibody protection, and kidney histopathological scores in SLE. These findings not only deepen our understanding of SLE pathogenesis but also further de-risk the continued clinical development of NIM-1324 for lupus patients. At NImmune Biopharma, Inc, we're committed to advancing I&I precision medicines by developing first-in-class, biomarker-driven therapeutics that address unmet clinical needs in autoimmune and inflammatory diseases. A big thank you to our dedicated teams and collaborators who made this breakthrough possible. Together, we're one step closer to delivering novel therapeutic options that could significantly improve patient outcomes. Read the full announcement here: https://lnkd.in/gjWM46SY #PrecisionMedicine #AutoimmuneDisease #SLE #ImmunologyResearch

NImmune Biopharma, Inc is at the forefront of AI-enabled drug development with a Phase 3 first-in-class therapeutic for IBD! The proven computational power of TITAN-X accelerates the path to the next wave of I&I precision medicines. TITAN-X has been validated through the acquisition of NX-13 (now called ABBV-113) and other drug candidates by AbbVie and through the clinical success of NImmune’s late stage I&I therapeutic pipeline. In his latest article, our Founder and CEO, Josep B., unveils how AI is fast-tracking the future of medicine. The piece discusses how the TITAN-X platform accelerates precision I&I drug development, significantly reducing time and costs while improving the odds of success by integrating cutting-edge AI with advanced computational modeling and bioinformatics. TITAN-X, licensed exclusively from The NIMML Institute, makes drug discovery and development faster, cheaper and better. NImmune’s AI-driven approach has already yielded impressive results, leading to two promising therapeutic candidates: Omilancor, currently in Phase 3 clinical development for ulcerative colitis and Phase 2 clinical development for Crohn’s disease, and NIM-1324, which is Phase 2-ready for lupus and rheumatoid arthritis. TITAN-X underpins NImmune’s pipeline of clinical and preclinical I&I product candidates and innovative therapeutic targets that aim to improve outcomes for millions of patients worldwide. https://lnkd.in/gpjYK6MS #AIinHealthcare #DrugDiscovery #BiopharmaInnovation #PrecisionMedicine

We're excited to share that NImmune Biopharma, Inc will be participating in the UBS Virtual Biotechnology Private Company Symposium on September 18-19, 2024.   We look forward to sharing our vision for the next wave of inflammation and immunology (I&I) precision medicines. https://lnkd.in/grsy4i3s    #BiotechSymposium #UBS #PrecisionMedicine

AI is revolutionizing drug discovery, and we're leading the charge! Our founder and CEO, Josep B., breaks down how the TITAN-X platform is accelerating precision I&I drug development in Pharmaceutical Executive. Discover how we're using AI to fast-track life-changing therapies and reshape the future of precision medicine. Read the full article: https://lnkd.in/gZ2RKBrD #AIinDrugDiscovery #PrecisionMedicine #BiopharmaInnovation

We're thrilled to announce NImmune Biopharma's new R&D collaboration with BioTherapeutics Inc. This partnership will enhance our capabilities by leveraging BioTherapeutics' computational and preclinical services to accelerate the biomarker-driven development of our LANCL immunoregulatory drug pipeline. We'll gain access to proprietary animal models, PK/PD analysis, and regulatory expertise, strengthening our research capabilities.   This collaboration, combined with our existing partnership with NIMML Institute's TITAN-X A.I. platform, creates a powerful scientific ecosystem driving innovation from discovery through clinical testing. At NImmune, we're committed to developing safer, more effective immunoregulatory therapeutics for patients with inflammatory and autoimmune diseases. This collaboration marks a significant step forward in our mission. Read the full announcement here: https://lnkd.in/dazvky5J    #PrecisionMedicine #Immunology #BiotechCollaboration #DrugDiscovery

We are excited to share that our Founder and CEO, Josep B., was recently featured on BioEmprendedores, a growing Spanish-language podcast focused on the broader biopharma sector. In this episode in Europe, Josep elaborates on the innovative work at NImmune Biopharma, Inc, particularly our focus on developing the next wave of biomarker-based precision medicines for inflammatory and autoimmune diseases. He discusses the journey of omilancor, our Phase 3 lead oral, once-daily, first-in-class therapeutic for ulcerative colitis and Crohn’s disease with a novel mechanism of action, and the strategic direction of our company. This episode provides a deep dive into the future of precision immunology and our commitment to transforming healthcare.   Listen to the full podcast is here: https://lnkd.in/grpBHcqd   #BioEmprendedores #PrecisionImmunology #Healthcare #Innovation #Biopharma

NImmune Biopharma, Inc’s Founder, Executive Chairman & CEO Josep B. was recently honored as a Virginia Success Story at THRiVE, Virginia Bio’s largest conference of the year. Dr. Bassaganya-Riera described his role in building a thriving biotech innovation ecosystem from the ground up, encompassing NImmune Biopharma, The NIMML Institute, and BioTherapeutics Inc., alongside Landos Biopharma, Inc., which was recently acquired by AbbVie. He underscored the groundbreaking potential of NImmune’s therapeutics in addressing the unmet clinical needs of millions of patients suffering from autoimmune diseases worldwide. NImmune’s lead drug, omilancor, is a first-in-class, best-in-class, oral, once-daily therapeutic in Phase 3 clinical development with a planned NDA filing for Ulcerative Colitis by 2026 and in Phase 2 clinical development for Crohn’s disease. Additionally, NIM-1324, a first-in-class, oral, once-daily, systemically distributed LANCL2 agonist, is in Phase 2 clinical development for the treatment of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis and other undisclosed indications. Watch Dr. Bassaganya-Riera’s full remarks below.   #VirginiaBio #THRiVE #PrecisionMedicine #LANCL2